The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Investing.com -- Novo Nordisk (CSE: NOVOb) (NYSE: NVO) shares slumped Wednesday after Roche (SIX: ROG) struck a $5.3 billion ...

BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, ...

The agreement covering the compound petrelintide, announced by Roche on Wednesday, marks renewed efforts to catch up with weight-loss market leaders Novo Nordisk and Eli Lilly .

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipeline.

Mette Frederiksen met with Giorgia Meloni. Despite the two prime ministers being on opposite political sides (Giorgia Meloni leads the right-wing Italian government), the two have shown agreement on ...

Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...

New York, New York-- (Newsfile Corp. - March 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, ...

Shares of Danish obesity-drug maker Novo Nordisk, which provided clinical trial data from its CagriSema product that disappointed investors on Monday, continued their retreat, and are down about 11% ...

Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...

Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity.

For the final quarter of 2024, the fund returned -5.12%, outpacing the -7.58% result of the benchmark MSCI All Country World ...